Piper Sandler raises Mondelez stock price target on better outlook By Investing.com

Piper Sandler raised Mondelez’s price target to $65 from $64 and lifted its 2026/2027 EPS estimates to $2.95 and $3.33, respectively, while keeping a Neutral rating. The company also posted a first-quarter 2026 beat, with EPS of $0.67 versus $0.61 consensus and revenue of $10.08 billion, plus a 3.0% organic growth rate. Management remains cautious on macro conditions and plans to reinvest cocoa-cost savings into growth, including innovation and key brand investments.

Analysis

The market is likely underestimating how much of MDLZ’s current setup is a margin-management story rather than a pure demand story. Reinvesting cocoa-cost savings into pricing, distribution, and innovation should support top-line durability, but it also caps near-term earnings torque; that makes this a slower-moving compounder rather than a clean leverage-to-commodities trade. The second-order winner is likely the company’s route-to-market ecosystem in India, Brazil, and parts of Europe, where incremental cooler placement and localized innovation can widen shelf share before smaller rivals can respond.

The key competitive dynamic is that private label pressure matters less than it looks if the branded player is willing to trade some near-term gross margin for share defense. That tends to hurt mid-tier regional snack producers more than it hurts global incumbents, because they lack scale to fund promotion and innovation simultaneously. Watch for supplier and retailer effects: if cocoa relief is being recycled into spending, the net benefit may flow to packaging, logistics, and field sales partners before it shows up in EPS.

Catalyst-wise, the next 1-2 quarters matter more than the next year: the stock can rerate modestly if management continues to print low-single-digit organic growth with stable share, but the upside is bounded unless reinvestment starts translating into visible volume acceleration. The tail risk is that consumer trade-down intensifies in Germany/France and promotional intensity rises faster than expected, forcing a margin reset. Another risk is that consensus becomes too comfortable with “conservative guidance” and misses that reinvestment can suppress earnings beats even while the business is healthy.

The contrarian view is that the market may be too focused on earnings revisions and not enough on the quality of those revisions: if higher estimates are driven by temporary input relief rather than sustainable productivity, the multiple can stall. That makes MDLZ better suited to being owned for dividend stability and downside defense than as an aggressive upside trade. The current setup looks more like a low-volatility compounder with optionality from execution in emerging markets than a near-term breakout candidate.

Key Decisions for Investors

• Hold/accumulate MDLZ on weakness only; use a 1-3 month horizon and treat it as a defensive compounder, not a momentum long. Risk/reward is favorable for income and downside protection, but upside is likely capped unless volume inflects.
• Pair trade: long MDLZ / short a higher-beta branded snacks or packaged-food peer with weaker scale and less pricing power over the next 2-4 months. Thesis: MDLZ can fund promotion and innovation through reinvestment, while smaller peers face margin compression.
• Buy MDLZ calls only as a low-cost earnings/event hedge if you expect another quarter of positive estimate revisions; prefer 2-4 month dated options with limited premium outlay. The trade works if management converts reinvestment into share gains faster than consensus expects.
• Do not chase the stock above fair-value multiples unless management signals a shift from reinvestment to EPS conversion. If the market starts pricing the cocoa benefit as permanent margin expansion, fade that move into strength.